Rhelion Life Sciences Corp. (CSE:RHEL)
0.0200
+0.0050 (33.33%)
At close: Nov 20, 2026
Rhelion Life Sciences Revenue
Rhelion Life Sciences had revenue of 186.07K CAD in the quarter ending June 30, 2026, a decrease of -66.35%. This brings the company's total for the last twelve months to 3.83M, down -2.80% year-over-year. In the fiscal year ending March 31, 2026, Rhelion Life Sciences had annual revenue of 4.20M, down -15.15%. That makes Rhelion Life Sciences the 41,788th largest company in the world by revenue and 809th in Canada.
Revenue (ttm)
3.83M
Revenue Growth
-2.80%
P/S Ratio
2.41
Revenue / Employee
n/a
Employees
n/a
Market Cap
12.28M
Revenue by Geography
- Netherlands 3.34M 79.5%
- Canada 860.06K 20.5%
- USA 117.00 0.0%
Fiscal year ended Mar 31, 2026 See the full Rhelion Life Sciences breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.20M | -749.01K | -15.15% |
| Mar 31, 2025 | 4.94M | 192.40K | 4.05% |
| Mar 31, 2024 | 4.75M | 802.31K | 20.31% |
| Mar 31, 2023 | 3.95M | 1.62M | 69.84% |
| Mar 31, 2022 | 2.33M | 2.21M | 1,995.96% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Rhelion Life Sciences News
- 1 day ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate - Newsfile Corp
- 3 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to UCSF for Phase 1 Trial of Psilocybin in Healthy Older Adults with Low Well-Being - Newsfile Corp
- 11 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to King's College London - Newsfile Corp
- 17 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Southern California for the Expanded Mindfulness Assisted Psychedelic Therapy Trial - Newsfile Corp
- 18 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing - Newsfile Corp
- 23 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder - Newsfile Corp
- 5 weeks ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression - Newsfile Corp
- 5 weeks ago - Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor - Newsfile Corp